P
PALISADE BIO INC
NASDAQ: PALI (Palisade Bio, Inc.)
Last update: 1 hour ago1.99
0.03 (1.53%)
| Previous Close | 1.96 |
| Volume | 730,430 |
| Price / Sales | 621.46 |
| Price / Book | 2.81 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -6.07 |
| Total Debt/Equity (MRQ) | 1.09% |
| Current Ratio (MRQ) | 2.84 |
| Operating Cash Flow (TTM) | -11.35 M |
| Levered Free Cash Flow (TTM) | -7.37 M |
| Return on Assets (TTM) | -80.94% |
| Return on Equity (TTM) | -170.72% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Palisade Bio, Inc. | Mixed | Bearish |
AIStockmoo Score
0.8
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -0.5 |
| Average | 0.83 |
|
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.46% |
| % Held by Institutions | 5.43% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| B Group, Inc. | 30 Jun 2026 | 11,414,285 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |